The niche where IGF-1 LR3 consistently outperforms: acute recovery from injury or training overreach
It is offered under compounding regulations and is intended for use within a medically supervised protocol
Enzyme Induction Involving the Ah Receptor Halogenated aromatic hydrocarbons including polybrominated biphenyls, polychlorinated biphenyls, various dioxins including the potent 2,3,7,8-tetrachlorodibenzodioxin (TCDD), and dibenzylfurans, as well as the protypical inducer 3-methylcholanthrene, act by binding to the intracellular Ah receptor (AhR) (Carlson and Perdew 2002
doi: 10.1128/AAC.49.8.3281-3288.2005 21 StinsonMWHaydenC
The FDA has identified concerns involving: Potential immunogenicity Peptide-related impurities Limited safety information for proposed routes of administration Insufficient information to determine whether compounded BPC-157 may cause harm in humans This does not prove that every patient who receives BPC-157 will experience a serious adverse event